Results 141 to 150 of about 2,016,148 (297)
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Molecular Oncology, EarlyView.Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source
PLASMA CELL NEOPLASM IN BREAST: A RARE CASE REPORT [PDF]
Monika Tripathi, Peijun Shen
openalex +1 more source
Breast neoplasm with distinct histological subtypes: A case report
, 2023 Rosana Zabulon Feijó Belluco +7 more
openalex +1 more source
NCI CTEP SDC Breast Neoplasm, Miscellaneous Sub-Category Terminology [PDF]
, 2020 National Cancer Institute
openalex +1 more source
FEBS Open Bio, EarlyView.Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel +9 more
wiley +1 more source
FEBS Open Bio, EarlyView.CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee +3 more
wiley +1 more source
Unveiling Rare Breast Neoplasms: Diagnostic Challenges and Insights. [PDF]
Discoveries (Craiova)Mohamedali R +7 more
europepmc +1 more source